Alset EHome International Inc. Prices $32.0 Million Underwritten Public Offering of Units
ACCESSWIRE
BETHESDA, MD / ACCESSWIRE / May 10, 2021 /
Alset EHome International Inc. (NASDAQ:AEI) (the Company ),
a diversified holding company principally engaged through its subsidiaries in property development, digital transformation technology and biohealth activities, today announced the pricing of an underwritten public offering (the Offering ) of 4,700,637 Units (the Common Units ), at a price to the public of $5.07 per Common Unit, with each Common Unit consisting of (a) one share of common stock, par value $0.001 per share (the Common Stock ), (b) one Series A warrant to purchase one share of Common Stock with an initial exercise price of $5.07 per whole share and (c) one Series B warrant to purchase one-half of a share of Common Stock with an initial exercise price of $6.59 per whole share. The Series A Warrants and Series B Warrants will be exercisable immediately upon issuan
Share this article
Share this article
WHIPPANY, N.J., May 6, 2021 /PRNewswire/ Suburban Propane Partners, L.P. (NYSE:SPH), today announced earnings for its second quarter ended March 27, 2021.
Net income for the second quarter of fiscal 2021 was $127.2 million, or $2.03 per Common Unit, compared to net income of $77.4 million, or $1.24 per Common Unit, in the prior year second quarter. Adjusted EBITDA (as defined and reconciled below) increased $41.4 million, or 31.7%, to $172.0 million for the second quarter of fiscal 2021, compared to $130.6 million in the prior year second quarter.
In announcing these results, President and Chief Executive Officer Michael A. Stivala said, The fiscal 2021 second quarter presented some of the most sustained and widespread cold weather that our service territories have experienced since 2015. As a result, propane volumes increased more than 16% compared to the prior year second quarter, as customer demand for heating purposes surged at a ti
Form 8-K SUBURBAN PROPANE PARTNER For: May 06 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- MultiXthin – For Flouroscopy market
Voyageur is prepared to test its newly-formulated products under GMP and HC guidelines and advance to clinical testing. Voyageur plans to ensure that it is creating the highest quality products prior to phase one marketing, sales and distribution to Canadian, USA and international markets.
Voyageur has begun the process to prepare applications for
FDA device registrations. Based on the new regulatory change of barium sulfate being designated as a device, versus its previous designation as a drug, Voyageur plans to move forward with a marketing and sales strategy for the US market.
Further to news releases dated April 13 and 23, 2021, the Company announces that it has closed the first tranche of a non-brokered private placement of common units ( Common Units ) and flow-through units ( Flow-Through Units ) (the Offering ). The Offering was a combination of (i) Common Units issued at a price of $0.15 per Common Unit and comprised of one (1)
Voyageur Pharmaceuticals Ltd. Issued 4th Health Canada License For Radiographic Barium Contrast Product
Brand Story
Voyageur Pharmaceuticals Ltd. (
TSX.V:VM) (
OTC:VYYRF) (the Company or Voyageur ) is pleased to announce that it has received approval from Health Canada (HC) for its product,
MultiXthin barium sulfate suspension. MultiXthin is specifically designed for single contrast radiographic examinations of the oesophagus, stomach, and small bowel to visualize the gastrointestinal (GI) tract in adult and pediatric patients.
Voyageur has built a suite of barium radiographic contrast media products for global sales and distribution. The following products have been licensed:
- SmoothX - For CT market